LUCY MUIGAI: Open Payments
NPI 1043437809 · WEST SPRINGFIELD, MA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,013 in 78 payments from 16 companies in 2025. Trend: 2023 $3,208 · 2024 $1,849 · 2025 $2,013
Food & beverage: $1,790Education: $223
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 14 | $533 |
| Otsuka America Pharmaceutical, Inc. | 12 | $255 |
| Gilead Sciences, Inc. | 9 | $241 |
| Lilly USA, LLC | 8 | $190 |
| ABBVIE INC. | 5 | $106 |
| Neurocrine BioSciences, Inc. | 4 | $106 |
| Biogen, Inc. | 5 | $100 |
| Aimmune Therapeutics, Inc. | 4 | $81 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $75 |
| GlaxoSmithKline, LLC. | 3 | $71 |
Products named: REXULTI, AUSTEDO XR, MOUNJARO, INGREZZA, LEQEMBI, VRAYLAR, UZEDY, CAPLYTA.
Industry payments across MA — which companies pay providers there.
